A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

NCT04660643 on ClinicalTrials.gov · last registry update 2024-05-22

Finished 25 April 2023, after enrolling 783 people. Primary outcome, as filed: Percent Change From Randomization in Body Weight at Week 88. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 783
Started: 2021-03-29
Primary completion: 2023-04-25 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Randomization in Body Weight at Week 88

Conditions studied

Obesity · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.